Halis Akturk

Dr. Akturk is a board-certified physician in Endocrinology, Diabetes and Metabolism and Internal Medicine. He serves as Communications Director of American Diabetes Association (ADA), Diabetes Technology Interest Group. He received Top Scoring Abstract Honor and one of the Young Investigator Award in 2019 ADA Annual Meeting. He is the founder and program director of Diabetes Dialog, an educational program and diabetes technology workshop for nationwide endocrinology fellows. He has significant amount of publications and he is a reviewer for many leading diabetes journals.

Main Research Interests:

1. Advanced Diabetes Technologies and Therapeutics: Dr. Akturk involved as a PI and sub-PI in several artificial pancreas, hybrid-closed loop, continuous glucose monitoring (CGM) studies, and faster insulins. To highlight some of his recent contributions last year; he was the PI for PROMISE, STAT, PRONTO, and REMD studies investigated 6-month implantable CGM, inhaled insulin, faster bolus insulin, and adjunctive therapies in type 1 diabetes, respectively. He described a new method to easily locate implanted glucose sensors using near-infrared light technology to facilitate removal.

2. Immune Checkpoint Inhibitor Induced Type 1 Diabetes: Cancer immunotherapies are revolutionary treatments, but they have autoimmune adverse effects. Dr. Akturk identified the similarities and differences between cancer immunotherapy induced and childhood-onset type 1 diabetes and one of the leading researchers in this field